Botanix Pharmaceuticals’ (ASX:BOT) resubmission of its New Drug Application for Sofdra has been accepted by the U.S. FDA. As a result, approval of the gel is targeted for June 2024 | ASX Announcement: https://announcements.asx.com.au/asxpdf/20240122/pdf/05zm3xd62ktg15.pdf #FDA #DrugApproval #ASX